cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-1638Research ArticleОБЗОРЫREVIEWSАнтитромбоцитарные препараты при острых коронарных синдромах и чрескожных коронарных вмешательствах: в фокусе тирофибанAntiplatelet medications in acute coronary syndromes and percutaneous coronary interventions: focus on tirofibanБатыралиевТ. А.BatyralievT. A.talantbekb@yahoo.comПреображенскийД. В.PreobrazhenskyD. V.talantbekb@yahoo.comФетцерД. В.FetzerD. V.talantbekb@yahoo.comСидоренкоБ. А.SidorenkoB. A.talantbekb@yahoo.comПатараяС. А.PatarayaS. A.talantbekb@yahoo.comМедицинский центр имени Сани Конукоглы, г. ГазиантепSani Konukogly Medical Center. GaziantepУчебно-научный медицинский центр Управления делами Президента Российской Федерации, г. МоскваEducational and Research Medical Center, RF President Administration. Moscow200820122008767988Copyright © Батыралиев Т.А., Преображенский Д.В., Фетцер Д.В., Сидоренко Б.А., Патарая С.А., 20082008Батыралиев Т.А., Преображенский Д.В., Фетцер Д.В., Сидоренко Б.А., Патарая С.А.Batyraliev T.A., Preobrazhensky D.V., Fetzer D.V., Sidorenko B.A., Pataraya S.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1638острый коронарный синдромчрескожное коронарное вмешательствоингибиторы IIb/IIIa рецепторов тромбоцитовтирофибанабциксимабэптифибатидacute coronary syndromepercutaneous coronary interventionplatelet IIb/IIIa receptor inhibitorstirofibanabciximabeptifibatideReferencesFuster V., Badimon L., Badimon J.J., Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N. Engl. J. Med. 1992; 326: 242-50.Fuster V., Badimon L., Badimon J.J., Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N. Engl. J. Med. 1992; 326: 242-50.Fuster V., Badimon L., Badimon J.J., Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N. Engl. J. Med. 1992; 326: 310-8.Fuster V., Badimon L., Badimon J.J., Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N. Engl. J. Med. 1992; 326: 310-8.White H. Unstable angina: Ischemic syndromes. In: Textbook of cardiovascular medicine. Topol E. (ed.). 3d edition. Philadelphia 2007; 251-79.White H. Unstable angina: Ischemic syndromes. In: Textbook of cardiovascular medicine. Topol E. (ed.). 3d edition. Philadelphia 2007; 251-79.Topol E., van de Werf F.J. Acute myocardial infarction -In: Textbook of cardiovascular medicine. Topol E. (ed.). 3d edition. Philadelphia 2007; 280-302.Topol E., van de Werf F.J. Acute myocardial infarction -In: Textbook of cardiovascular medicine. Topol E. (ed.). 3d edition. Philadelphia 2007; 280-302.Cohen M. Treatment of unstable angina: The role of platelet inhibitors and anticoagulants. J. Invasive Cardiology 1999; 11: 147-59.Cohen M. Treatment of unstable angina: The role of platelet inhibitors and anticoagulants. J. Invasive Cardiology 1999; 11: 147-59.Meier B. Percutaneous coronary intervention. -In: Textbook of cardiovascular medicine. Topol E. (ed.). 3d edition. Philadelphia 2007; 1258-89.Meier B. Percutaneous coronary intervention. -In: Textbook of cardiovascular medicine. Topol E. (ed.). 3d edition. Philadelphia 2007; 1258-89.Becker R.C., Fintel D.J., Green D. Antithrombotic therapy. 4th edition. New York 2006.Becker R.C., Fintel D.J., Green D. Antithrombotic therapy. 4th edition. New York 2006.Shimbo D., Pickering Th. Platelet in cardiovascular and noncardiovascular disorders: pathophysiology, pharmacology, and therapeutics. Cardiovascular Reviews & Reports 2004; 25: 18-24.Shimbo D., Pickering Th. Platelet in cardiovascular and noncardiovascular disorders: pathophysiology, pharmacology, and therapeutics. Cardiovascular Reviews & Reports 2004; 25: 18-24.Б.А. Сидоренко, Д.В. Преображенский. Клиническое применение антитромботических препаратов. Москва 1998.Б.А. Сидоренко, Д.В. Преображенский. Клиническое применение антитромботических препаратов. Москва 1998.Bhatt D.L., Topol E.J. Scientific and therapeutic advances in anti-platelet therapy. Nature Reviews 2003; 2: 15-28.Bhatt D.L., Topol E.J. Scientific and therapeutic advances in anti-platelet therapy. Nature Reviews 2003; 2: 15-28.Messmore Jr.H.L., Wehrmacher W.H., Cayne E., Jeske W. The clinical utility of antiplatelet drugs revised. Cardiovascular Reviews & Reports 2004; 25: 29-32.Messmore Jr.H.L., Wehrmacher W.H., Cayne E., Jeske W. The clinical utility of antiplatelet drugs revised. Cardiovascular Reviews & Reports 2004; 25: 29-32.Topol E.J., Byzova T.V., Plow E.F. Platelet GP IIb/IIIa blockers. Lancet 1999; 353: 227-31.Topol E.J., Byzova T.V., Plow E.F. Platelet GP IIb/IIIa blockers. Lancet 1999; 353: 227-31.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction. Lancet 1988; 2: 349-60.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction. Lancet 1988; 2: 349-60.Konig D.F., Hasselblad V., Kandzari D.E., et al. Seeking the optimal aspirin dose in acute coronary syndromes. Am. J. Cardiol. 2002; 90: 622-5.Konig D.F., Hasselblad V., Kandzari D.E., et al. Seeking the optimal aspirin dose in acute coronary syndromes. Am. J. Cardiol. 2002; 90: 622-5.Yusuf S., Zhao F., Merita S.R., et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New Engl. J. Med. 2001; 345: 494-502.Yusuf S., Zhao F., Merita S.R., et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New Engl. J. Med. 2001; 345: 494-502.Mehta S.R., Yusuf S., Peters R.J., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention; the PCI-CURE study. Lancet 2001; 358: 527-33.Mehta S.R., Yusuf S., Peters R.J., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention; the PCI-CURE study. Lancet 2001; 358: 527-33.Steinhubl S.R., Berger P.B., Mann J.T. III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. JACC 2002; 288: 2411-20.Steinhubl S.R., Berger P.B., Mann J.T. III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. JACC 2002; 288: 2411-20.The GUSTO-IV ACS investigators. Effect of glycoprotein IIb/ IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revasculariza- tion: the GUSTO-IV ACS. Lancet 2001; 357: 1915–24.The GUSTO-IV ACS investigators. Effect of glycoprotein IIb/ IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revasculariza- tion: the GUSTO-IV ACS. Lancet 2001; 357: 1915–24.Cook JJ, Bednar B, Lynch JJ, et al. Tirofiban (Aggrastat). Cardiovascular Drug Reviews 1999; 17: 199–224.Cook JJ, Bednar B, Lynch JJ, et al. Tirofiban (Aggrastat). Cardiovascular Drug Reviews 1999; 17: 199–224.The RESTORE investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in unstable angina or myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96: 1445–53.The RESTORE investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in unstable angina or myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96: 1445–53.The RESTORE investigators. Six month angiographic and clinical follow-up of patients prospectively randomized to either tirofiban or placebo during in the RESTORE. JACC 1998; 32: 28–34.The RESTORE investigators. Six month angiographic and clinical follow-up of patients prospectively randomized to either tirofiban or placebo during in the RESTORE. JACC 1998; 32: 28–34.Valgimigli M, Percoco G, Barbieri D, et al. The additive value of tirofiban administrated with high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty. JACC 2004; 44: 14–9.Valgimigli M, Percoco G, Barbieri D, et al. The additive value of tirofiban administrated with high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty. JACC 2004; 44: 14–9.The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) study investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. New Engl J Med 1998; 338: 1498–505.The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) study investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. New Engl J Med 1998; 338: 1498–505.The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and symp- toms (PRISMPLUS) study investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and nonQwave myocardial infarction. N Engl J Med 1998; 338: 1488–97.The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and symp- toms (PRISMPLUS) study investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and nonQwave myocardial infarction. N Engl J Med 1998; 338: 1488–97.Morrow D, Antman EM, Snapinn SM, et al. An integrated clinical approach to predicting the benefit of tirofiban in non-ST-segment elevation acute coronary syndromes: Application of the TIMI risk score for UA/NSTEMI in PRISM-PLUS. Eur Heart J 2002; 23: 223–9.Morrow D, Antman EM, Snapinn SM, et al. An integrated clinical approach to predicting the benefit of tirofiban in non-ST-segment elevation acute coronary syndromes: Application of the TIMI risk score for UA/NSTEMI in PRISM-PLUS. Eur Heart J 2002; 23: 223–9.Morrow D, Sabatine M, Cannon C, et al. Benefit of tirofiban among patients treated without coronary intervention: Application of the TIMI risk score for unstable angina and non-ST-segment elevation myocardial infarction in PRISM-PLUS. Circulation 2002; 104 (Suppl. II): 782 (abstract).Morrow D, Sabatine M, Cannon C, et al. Benefit of tirofiban among patients treated without coronary intervention: Application of the TIMI risk score for unstable angina and non-ST-segment elevation myocardial infarction in PRISM-PLUS. Circulation 2002; 104 (Suppl. II): 782 (abstract).Martinez-Rios MA, Rosas M, Gonzalez H, et al. Comparison of reperfusion regimens with or without tirofiban in ST-elevation acute myocardial infarction. Am J Cardiol 2004; 93: 280–7.Martinez-Rios MA, Rosas M, Gonzalez H, et al. Comparison of reperfusion regimens with or without tirofiban in ST-elevation acute myocardial infarction. Am J Cardiol 2004; 93: 280–7.Roffi M, Topol E. Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J 2004; 25: 190–8.Roffi M, Topol E. Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J 2004; 25: 190–8.Roffi M, Chew DP, Makherjee D, et al. Platelet glycopro- tein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation 2001; 104: 2767–71.Roffi M, Chew DP, Makherjee D, et al. Platelet glycopro- tein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation 2001; 104: 2767–71.Boersma E, Harrington RA, Moliterno DJ, et al. Platelet gly- coprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised trials. Lancet 2002; 359: 189–98.Boersma E, Harrington RA, Moliterno DJ, et al. Platelet gly- coprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised trials. Lancet 2002; 359: 189–98.Chew DP, Moliterno DJ. A critical appraisal of platelet glycopro- tein IIb/IIIa inhibition. JACC 2000; 36: 2028–35.Chew DP, Moliterno DJ. A critical appraisal of platelet glycopro- tein IIb/IIIa inhibition. JACC 2000; 36: 2028–35.Topol E, Moliterno D, Herrmann H, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percu- taneous coronary revascularization. N Engl J Med 2001; 344: 1888–94.Topol E, Moliterno D, Herrmann H, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percu- taneous coronary revascularization. N Engl J Med 2001; 344: 1888–94.Kandzari DE, Califf RM. TARGET versus GUSTO-IV: appro- priate use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes and percutaneous coronary intervention. Current Opin Cardiol 2002; 17: 332–9.Kandzari DE, Califf RM. TARGET versus GUSTO-IV: appro- priate use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes and percutaneous coronary intervention. Current Opin Cardiol 2002; 17: 332–9.Chew DP, Moliterno DJ. A critical appraisal of platelet glycopro- tein IIb/IIIa inhibition. JACC 2000; 36: 2028–35.Chew DP, Moliterno DJ. A critical appraisal of platelet glycopro- tein IIb/IIIa inhibition. JACC 2000; 36: 2028–35.Steinhubl SR, Talley JD, Braden GA, et al. Pointof care measured platelet inhibition correlates with a rediced risk of an adverse cardiac event after percutaneous coronary revasculariza- tion. Results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001; 103: 2572–8.Steinhubl SR, Talley JD, Braden GA, et al. Pointof care measured platelet inhibition correlates with a rediced risk of an adverse cardiac event after percutaneous coronary revasculariza- tion. Results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001; 103: 2572–8.
The authors declare that there are no conflicts of interest present.